Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylamine SCHEMBL6014499 | 0.93 | TAAR1 (0.53) | TAAR1HRH1HTR2ASLC7A5RIPK1 | |
| SCHEMBL190949 | 0.86 | RIPK1 (0.59) | TAAR1RIPK1AOC3TRPA1 | |
| Butylamine SCHEMBL9108736 | 0.85 | HRH1 (0.67) | TAAR1HRH1HTR2ASLC7A5AOC3 | |
| SCHEMBL2096805 | 0.84 | HRH1 (0.65) | TAAR1HRH1HTR2ASLC7A5RIPK1 | |
| Hydrogen Peroxide SCHEMBL2352060 | 0.84 | RIPK1 (0.57) | TAAR1RIPK1AOC3TRPA1 | |
| Ammonia Solution, Strong SCHEMBL6014394 | 0.84 | RIPK1 (0.57) | TAAR1RIPK1AOC3TRPA1 | |
| SCHEMBL3428511 | 0.82 | TAAR1 (0.59) | TAAR1HRH1HTR2ASLC7A5RIPK1 | |
| SCHEMBL14387157 | 0.82 | TAAR1 (0.59) | TAAR1HRH1HTR2ASLC7A5RIPK1 | |
| SCHEMBL190051 | 0.82 | RIPK1 (0.55) | TAAR1RIPK1AOC3TRPA1POLB | |
| SCHEMBL14459040 | 0.81 | TAAR1 (0.57) | TAAR1HRH1HTR2ASLC7A5RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078406-B2 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | Life Technologies Corporation | 2004-12-09 | — | — | US | disclosed |
| US-6815445-B2 | FOR USE AS FLUORESCENCE DYES AND PROBES | Life Technologies Corporation | 2004-11-09 | — | — | US | disclosed |
| EP-1442027-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | TAAR1 2085/4885HRH1 1821/4885HTR2A 2034/4885 |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | TAAR1 2085/4885HRH1 1821/4885HTR2A 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.